FDA Inspection 1240584 — Astellas Pharma Inc.
The FDA completed an inspection of Astellas Pharma Inc. on April 18, 2024 in Toyama. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 18, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Toyama (Japan)